Analyst: Genmab's Darzalex income coming in faster than expected

A Sydbank analyst following the Danish biotech firm is very interested in the accelerating sales of cancer drug Darzalex, which Genmab reported after Q2.

Photo: Joost Melis / Genmab / PR

Genmab’s golden egg, Darzalex, contributed more to Genmab’s overall incomes than expected by Sydbank in the second quarter of 2022.

The bank’s senior equity analyst, Søren Løntoft Hansen, also sees the sales of Tivdak, which Genmab is marketing alongside its partner, Seagen, as positive for the firm. Additionally, he notes that the Q2 result was boosted by a strengthened US dollar.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs